Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Utilizing comprehensive and mini-kinome panels to optimize the selectivity of quinoline inhibitors for cyclin G associated kinase (GAK).

Asquith CRM, Treiber DK, Zuercher WJ.

Bioorg Med Chem Lett. 2019 Jul 15;29(14):1727-1731. doi: 10.1016/j.bmcl.2019.05.025. Epub 2019 May 16.

2.

Donated chemical probes for open science.

Müller S, Ackloo S, Arrowsmith CH, Bauser M, Baryza JL, Blagg J, Böttcher J, Bountra C, Brown PJ, Bunnage ME, Carter AJ, Damerell D, Dötsch V, Drewry DH, Edwards AM, Edwards J, Elkins JM, Fischer C, Frye SV, Gollner A, Grimshaw CE, IJzerman A, Hanke T, Hartung IV, Hitchcock S, Howe T, Hughes TV, Laufer S, Li VM, Liras S, Marsden BD, Matsui H, Mathias J, O'Hagan RC, Owen DR, Pande V, Rauh D, Rosenberg SH, Roth BL, Schneider NS, Scholten C, Singh Saikatendu K, Simeonov A, Takizawa M, Tse C, Thompson PR, Treiber DK, Viana AY, Wells CI, Willson TM, Zuercher WJ, Knapp S, Mueller-Fahrnow A.

Elife. 2018 Apr 20;7. pii: e34311. doi: 10.7554/eLife.34311.

3.

Progress towards a public chemogenomic set for protein kinases and a call for contributions.

Drewry DH, Wells CI, Andrews DM, Angell R, Al-Ali H, Axtman AD, Capuzzi SJ, Elkins JM, Ettmayer P, Frederiksen M, Gileadi O, Gray N, Hooper A, Knapp S, Laufer S, Luecking U, Michaelides M, Müller S, Muratov E, Denny RA, Saikatendu KS, Treiber DK, Zuercher WJ, Willson TM.

PLoS One. 2017 Aug 2;12(8):e0181585. doi: 10.1371/journal.pone.0181585. eCollection 2017.

4.

Identification of a Chemical Probe for Family VIII Bromodomains through Optimization of a Fragment Hit.

Gerstenberger BS, Trzupek JD, Tallant C, Fedorov O, Filippakopoulos P, Brennan PE, Fedele V, Martin S, Picaud S, Rogers C, Parikh M, Taylor A, Samas B, O'Mahony A, Berg E, Pallares G, Torrey AD, Treiber DK, Samardjiev IJ, Nasipak BT, Padilla-Benavides T, Wu Q, Imbalzano AN, Nickerson JA, Bunnage ME, Müller S, Knapp S, Owen DR.

J Med Chem. 2016 May 26;59(10):4800-11. doi: 10.1021/acs.jmedchem.6b00012. Epub 2016 May 3.

5.

Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.

Ciceri P, Müller S, O'Mahony A, Fedorov O, Filippakopoulos P, Hunt JP, Lasater EA, Pallares G, Picaud S, Wells C, Martin S, Wodicka LM, Shah NP, Treiber DK, Knapp S.

Nat Chem Biol. 2014 Apr;10(4):305-12. doi: 10.1038/nchembio.1471. Epub 2014 Mar 2. Erratum in: Nat Chem Biol. 2014 Aug;10(8):692.

6.

Ins and outs of kinase DFG motifs.

Treiber DK, Shah NP.

Chem Biol. 2013 Jun 20;20(6):745-6. doi: 10.1016/j.chembiol.2013.06.001.

7.

Discovery of AC710, a Globally Selective Inhibitor of Platelet-Derived Growth Factor Receptor-Family Kinases.

Liu G, Campbell BT, Holladay MW, Ford Pulido JM, Hua H, Gitnick D, Gardner MF, James J, Breider MA, Brigham D, Belli B, Armstrong RC, Treiber DK.

ACS Med Chem Lett. 2012 Sep 24;3(12):997-1002. doi: 10.1021/ml300214g. eCollection 2012 Dec 13.

8.

Discovery of highly potent and selective pan-Aurora kinase inhibitors with enhanced in vivo antitumor therapeutic index.

Liu G, Abraham S, Tran L, Vickers TD, Xu S, Hadd MJ, Quiambao S, Holladay MW, Hua H, Ford Pulido JM, Gunawardane RN, Davis MI, Eichelberger SR, Apuy JL, Gitnick D, Gardner MF, James J, Breider MA, Belli B, Armstrong RC, Treiber DK.

J Med Chem. 2012 Apr 12;55(7):3250-60. doi: 10.1021/jm201702g. Epub 2012 Mar 14.

PMID:
22380736
9.

Comprehensive analysis of kinase inhibitor selectivity.

Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP.

Nat Biotechnol. 2011 Oct 30;29(11):1046-51. doi: 10.1038/nbt.1990.

PMID:
22037378
10.

Novel series of pyrrolotriazine analogs as highly potent pan-Aurora kinase inhibitors.

Abraham S, Hadd MJ, Tran L, Vickers T, Sindac J, Milanov ZV, Holladay MW, Bhagwat SS, Hua H, Ford Pulido JM, Cramer MD, Gitnick D, James J, Dao A, Belli B, Armstrong RC, Treiber DK, Liu G.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5296-300. doi: 10.1016/j.bmcl.2011.07.027. Epub 2011 Jul 14.

PMID:
21802948
11.

Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.

Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP, Treiber DK.

Chem Biol. 2010 Nov 24;17(11):1241-9. doi: 10.1016/j.chembiol.2010.09.010.

12.

Arylcarboxyamino-substituted diaryl ureas as potent and selective FLT3 inhibitors.

Patel HK, Grotzfeld RM, Lai AG, Mehta SA, Milanov ZV, Chao Q, Sprankle KG, Carter TA, Velasco AM, Fabian MA, James J, Treiber DK, Lockhart DJ, Zarrinkar PP, Bhagwat SS.

Bioorg Med Chem Lett. 2009 Sep 1;19(17):5182-5. doi: 10.1016/j.bmcl.2009.07.024. Epub 2009 Jul 9.

PMID:
19646870
13.

A quantitative analysis of kinase inhibitor selectivity.

Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP.

Nat Biotechnol. 2008 Jan;26(1):127-32. doi: 10.1038/nbt1358.

PMID:
18183025
14.

Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.

Young MA, Shah NP, Chao LH, Seeliger M, Milanov ZV, Biggs WH 3rd, Treiber DK, Patel HK, Zarrinkar PP, Lockhart DJ, Sawyers CL, Kuriyan J.

Cancer Res. 2006 Jan 15;66(2):1007-14.

15.

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.

Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK, Milanov ZV, Atteridge CE, Biggs WH 3rd, Edeen PT, Floyd M, Ford JM, Grotzfeld RM, Herrgard S, Insko DE, Mehta SA, Patel HK, Pao W, Sawyers CL, Varmus H, Zarrinkar PP, Lockhart DJ.

Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11011-6. Epub 2005 Jul 26.

16.

A small molecule-kinase interaction map for clinical kinase inhibitors.

Fabian MA, Biggs WH 3rd, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, Ford JM, Galvin M, Gerlach JL, Grotzfeld RM, Herrgard S, Insko DE, Insko MA, Lai AG, Lélias JM, Mehta SA, Milanov ZV, Velasco AM, Wodicka LM, Patel HK, Zarrinkar PP, Lockhart DJ.

Nat Biotechnol. 2005 Mar;23(3):329-36. Epub 2005 Feb 13.

17.

Beyond kinetic traps in RNA folding.

Treiber DK, Williamson JR.

Curr Opin Struct Biol. 2001 Jun;11(3):309-14. Review.

PMID:
11406379
18.

Concerted kinetic folding of a multidomain ribozyme with a disrupted loop-receptor interaction.

Treiber DK, Williamson JR.

J Mol Biol. 2001 Jan 5;305(1):11-21.

PMID:
11114243
19.

Kinetic oligonucleotide hybridization for monitoring kinetic folding of large RNAs.

Treiber DK, Williamson JR.

Methods Enzymol. 2000;317:330-53. No abstract available.

PMID:
10829289
20.

An optimal Mg(2+) concentration for kinetic folding of the tetrahymena ribozyme.

Rook MS, Treiber DK, Williamson JR.

Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12471-6.

21.

Exposing the kinetic traps in RNA folding.

Treiber DK, Williamson JR.

Curr Opin Struct Biol. 1999 Jun;9(3):339-45. Review.

PMID:
10361090
22.

Fast folding mutants of the Tetrahymena group I ribozyme reveal a rugged folding energy landscape.

Rook MS, Treiber DK, Williamson JR.

J Mol Biol. 1998 Aug 28;281(4):609-20.

PMID:
9710534
23.

Kinetic intermediates trapped by native interactions in RNA folding.

Treiber DK, Rook MS, Zarrinkar PP, Williamson JR.

Science. 1998 Mar 20;279(5358):1943-6.

24.

A CCHC metal-binding domain in Nanos is essential for translational regulation.

Curtis D, Treiber DK, Tao F, Zamore PD, Williamson JR, Lehmann R.

EMBO J. 1997 Feb 17;16(4):834-43.

25.

A simple method for preparing pools of synthetic oligonucleotides with random point deletions.

Treiber DK, Williamson JR.

Nucleic Acids Res. 1995 Sep 11;23(17):3603-4. No abstract available.

26.

Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor).

Treiber DK, Zhai X, Jantzen HM, Essigmann JM.

Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5672-6.

28.

Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin.

Donahue BA, Augot M, Bellon SF, Treiber DK, Toney JH, Lippard SJ, Essigmann JM.

Biochemistry. 1990 Jun 19;29(24):5872-80.

PMID:
2383564

Supplemental Content

Loading ...
Support Center